Hemab logo

Hemab

Website
Current Valuation
N/A
As of October 27, 2025
Total Funding Raised
$353.0M
Last Round
Later Stage VC

$157.0M

Last Funding
Oct 2025

Funding date

Capital Efficiency
N/A

Valuation / Funding

Funding History & Valuation Timeline
Complete history of all funding rounds and valuation milestones

No funding history available

Funding data has not been imported for this company yet

Valuation Analysis

Current Valuation Metrics

Hemab is currently valued at N/A as of October 27, 2025. The company has raised a total of $353.0M in funding.

Investment Perspective

Hemab's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.

Track Hemab Valuation Updates

Get notified when Hemab raises new funding or valuation changes

Explore More Data
Detailed analysis for Hemab

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

What is Hemab Worth in 2025?

As of 2025, Hemab is valued at N/A, based on the company's Later Stage VC funding round in October 27, 2025. This valuation positions Hemab as one of the leading private companies in the sector.

Hemab Valuation History

Hemab's funding history demonstrates steady growth and investor confidence.

How Hemab Valuation is Determined

Private company valuations like Hemab's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:

  • Revenue growth and financial performance
  • Market opportunity and total addressable market (TAM)
  • Competitive positioning and market share
  • Management team strength and execution capability
  • Technology and intellectual property
  • Industry trends and investor sentiment

Hemab Valuation FAQs

Is Hemab profitable?

Hemab has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.

How does Hemab's valuation compare to competitors?

Hemab is valued at N/A, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.

When will Hemab IPO?

Hemab has not announced plans for an initial public offering. Until an IPO, investors can access Hemab shares through secondary market platforms.